Business Context and Reporting Period
This Form 8-K Current Report was filed by Karyopharm Therapeutics Inc. on September 23, 2020, regarding events occurring on September 25, 2020. The filing addresses the departure of a senior executive and the associated transition arrangements.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on executive compensation and employment terms.
Material Changes
The primary material change is the departure of Christopher B. Primiano, Executive Vice President, Chief Business Officer, General Counsel, and Secretary. Mr. Primiano notified the Company of his intention to pursue other professional interests. A Transition Agreement was executed to manage his exit and continued service.
Outlook, Management Commentary, and Risks
Transition Arrangements: Mr. Primiano will continue in his current role until the earlier of March 19, 2021, or the fifth business day following FDA approval of the supplemental new drug application for XPOVIO based on the Phase 3 BOSTON study (the "Resignation Date").
Compensation Terms:
- Bonus: Mr. Primiano is eligible for his full target bonus for the fiscal year ending December 31, 2020, provided he does not resign without good reason or is not terminated for cause prior to that date.
- Equity: He is entitled to receive 2021 annual equity awards on the same basis as other executive officers in good standing.
- Post-Employment Benefits: If he remains employed through the Resignation Date or resigns for good reason/is terminated without cause, he will receive healthcare benefit premium payments until December 31, 2021.
- Consulting: The Company will engage Mr. Primiano as a consultant until December 31, 2021. His outstanding unvested equity awards and future grants will continue to vest during this period. An hourly consulting fee will be paid for hours worked beyond the fifth hour in any calendar month.
Risks and Contingencies: The receipt of the full target bonus, future equity grants, and post-employment benefits is contingent upon Mr. Primiano not resigning without good reason and not being terminated for cause prior to specific dates outlined in the agreement.
Investor Verification Checklist
- Verify the exact terms of the Transition Agreement and Consulting Agreement filed as Exhibits 10.1 and 10.2.
- Monitor the status of the Phase 3 BOSTON study and the FDA supplemental new drug application for XPOVIO, as this milestone determines the Resignation Date.
- Assess the potential financial impact of the consulting fees and continued equity vesting on the Company's future compensation expenses.
- Confirm the timeline for the appointment of a successor to Mr. Primiano's multiple roles (EVP, CBO, General Counsel, Secretary).